BioCentury | Sep 5, 2016
Clinical News

Engineered Skin Substitute: Compassionate use program data

...pediatric patients with life-threatening, full-thickness, severe burns covering >50% total body surface area showed that PermaDerm...
...rate of 6.25% vs. 30.3% for historic controls (p<0.05). One patient died before receiving PermaDerm. PermaDerm...
...Burn Care and Research. Amarantus BioScience Holdings Inc. (OTCQX:AMBS), San Francisco, Calif. Product: Engineered Skin Substitute (ESS) ( PermaDerm...
BioCentury | Oct 12, 2015
Clinical News

Eltoprazine: Phase IIb halted

...to eltoprazine from PsychoGenics (see BioCentury, Jan. 20, 2014). Amarantus will instead focus on its Engineered Skin Substitute (ESS)...
BioCentury | Dec 15, 2014
Company News

Regenicin, Amarantus BioScience deal

...Amarantus purchased IP related to Regenicin’s PermaDerm for $3.5 million in cash plus 37.5 million shares...
...Lonza $3 million for an exclusive license to purchase IP and manufacturing know-how related to PermaDerm...
...received the exclusive know-how license. Regenicin said it developed its own cultured skin substitute for PermaDerm...
BioCentury | Jun 18, 2012
Clinical News

PermaDerm regulatory update

...FDA granted Orphan Drug designation for PermaDerm to treat catastrophic burns. Regenicin has exclusive, worldwide rights...
...of Defense awarded a unit of Lonza more than $18 million to develop and commercialize PermaDerm...
...13, 2010). Lonza Group Ltd. (SIX:LONN), Basel, Switzerland Regenicin Inc. (OTCBB:RGIN), Little Falls, N.J. Product: PermaDerm...
BioCentury | Dec 13, 2010
Company News

Lonza Group AG, U.S. Department of Defense deal

...The DoD awarded a unit of Lonza more than $18 million to develop and commercialize PermaDerm...
BioCentury | Aug 23, 2010
Company News

Lonza Group AG, Regenicin deal

...year end an application to FDA for a Humanitarian Device Exemption for the technology as PermaDerm...
...the indication by year end 2011 or early 2012. Lonza retains exclusive manufacturing rights for PermaDerm...
BioCentury | Feb 13, 2006
Company News

Cutanogen Corp., Cambrex deal

...Cutanogen shareholders also are eligible for up to $4.8 million in milestones. Cutanogen's lead product, PermaDerm...
...covering at least 50% of the body. CBM expects to start a pivotal trial of PermaDerm...
Items per page:
1 - 7 of 7